GLP-1 maintenance tips on TikTok: what holds up and what doesn't

What's this video probably claiming?

Based on the hashtags #glp1maintenance, #glp1results, and #glp1tips, @slimpossible59 is almost certainly sharing personal experience with a GLP-1 receptor agonist, likely semaglutide or tirzepatide, and offering advice on staying on the medication, managing side effects, or holding onto weight loss results. This genre of video is everywhere right now. The creator's handle suggests a weight loss journey, and the #glp1community tag signals they're positioning themselves as a peer guide rather than a clinician. These videos typically include tips like "eat protein first," "stay hydrated," "start low and go slow on doses," and claims about how to avoid weight regain after stopping. Some go further and suggest specific dosing schedules or that certain supplements enhance GLP-1 effects. The maintenance angle is particularly worth scrutinizing, because the clinical data on what actually preserves GLP-1-driven weight loss is more complicated, and less encouraging, than most TikTok creators let on.

What does the science actually show?

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that participants on semaglutide 2.4 mg weekly lost an average of 14.9% of body weight over 68 weeks. That's real and meaningful. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at 15 mg produced up to 20.9% mean weight loss. Those are the headline numbers you'll see repeated across social media, and they're accurate. What gets buried is what happens after stopping. The STEP 4 withdrawal trial (Rubino et al., 2021, JAMA) followed patients who stopped semaglutide after 20 weeks and found they regained about two-thirds of their lost weight within 48 weeks post-discontinuation. Appetite and hunger hormones largely returned to baseline. Lifestyle interventions helped, but did not fully compensate. The biology here is not a willpower problem, it's a pharmacological dependency that the social media framing almost never addresses honestly.

Where does the social media noise diverge from clinical reality?

The biggest divergence is around the concept of "GLP-1 maintenance" itself. On TikTok, maintenance implies you can taper off the drug, lock in your results with the right habits, and be done. The clinical data says something much harder to hear: for most people, GLP-1 agonists function more like antihypertensives than antibiotics. You don't finish a course, you manage a chronic condition. A 2022 analysis in Obesity Reviews (Drucker, 2022) framed obesity as a relapsing biological condition, not a behavioral failure, which means discontinuing the medication often means restarting the underlying pathology. Beyond that, the supplement claims that appear in these videos, things like berberine as a "natural GLP-1" or fiber timing hacks, are largely extrapolated from mechanistic studies with no head-to-head weight loss data against actual GLP-1 medications. The "noise to signal" ratio in this content category is poor, and the people most likely to trust it are the ones who've already had real results and don't want to hear that those results are drug-dependent.

What should you actually know?

If you're on a GLP-1 agonist and watching videos about maintenance, the most useful thing to understand is that your prescriber should be driving this conversation, not a TikTok creator. That said, a few things are genuinely supported by evidence. Resistance training during GLP-1 treatment appears to help preserve lean muscle mass that would otherwise be lost alongside fat, based on data from Lundgren et al. (2021, Obesity). Adequate protein intake (studies generally suggest 1.2 to 1.6 grams per kilogram of body weight) supports the same goal. Behavioral strategies like structured eating patterns and sleep hygiene have modest but real supporting evidence as adjuncts. What is not supported: the idea that any supplement replicates or meaningfully extends GLP-1 drug effects. And the idea that weight regain after stopping is a personal failure rather than a predictable pharmacological outcome is not just unsupported, it's actively harmful to how patients understand their own treatment.